Beijing Keyoceanmed Pharmaceutical

Beijing Keyoceanmed Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the discovery of next-generation small molecule precision medicines. The company utilizes a proprietary structure-based drug design (SBDD) platform to develop highly selective kinase inhibitors for oncology and autoimmune disorders. Its lead candidate, KO-147, is a selective CDK4/6 inhibitor currently being evaluated for the treatment of advanced breast cancer. Other notable programs include KO-2706, a pan-TRK inhibitor targeting NTRK fusion-positive solid tumors, and KO-1048, a selective CDK7 inhibitor. Keyoceanmed aims to overcome drug resistance mechanisms associated with first-generation kinase inhibitors through superior selectivity and potency. The company is backed by prominent venture capital firms including Legend Capital and Northern Light Venture Capital.